

Aurealis Pharma to Present at BioTrinity 2015 - European Biopartnering and Investment Conference on May 12th 2015

Kuopio Finland, Basel Switzerland – April 16th 2015

Aurealis Pharma, a private biopharmaceutical company focused on chronic inflammation and oncology, announced today that CEO Juha Yrjänheikki will present the company and its progress on Tuesday, May 12th, 2015 at 2:40 pm. Dr. Yrjänheikki and CSO Dr. Thomas Wirth will attend at the BioTrinity 2015 Conference in London UK on May 11-13th 2015.

CEO Yrjänheikki said, “We are pleased to participate and present at the BioTrinity 2015 European Biopartnering and Investment Conference. We look forward to share our Company’s exciting story and progress with the targeted audience this prestigious conference presents.”

Aurealis Pharma is a Kuopio Finland and Basel Switzerland based privately-held biopharmaceutical company focusing on developing broadly applicable proprietary technology to effectively, safely and economically modulate and re-educate the distorted host immune microenvironment to its proper state in chronic inflammation and cancer. Company’s technology is based on safe food-grade lactic acid bacteria modified to produce and secreting multiple human therapeutic proteins in target tissue facilitating protein/antibody multitherapy in a single product.

BioTrinity, one of the leading European biopartnering and investment conference, brings together R&D companies, big pharma and medtech corporates, as well as biomedical investors. BioTrinity 2015 will be taking place at the Novotel London West, May 11-13th 2015.

For more information:

Juha Yrjänheikki, CEO
Aurealis Pharma
Microkatu 1
FI-70211 Kuopio
Finland
Tel: +358 45 8433550
Email: juha(at)aurealispharma.com
www.aurealispharma.com



AUREALIS PHARMA
Microkatu 1
FI-70210 Kuopio
Finland

www.aurealispharma.com